Home » Stocks » SYRS

Syros Pharmaceuticals, Inc. (SYRS)

Stock Price: $5.22 USD 0.13 (2.55%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 329.40M
Revenue (ttm) 17.54M
Net Income (ttm) -81.04M
Shares Out 61.38M
EPS (ttm) -1.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $5.22
Previous Close $5.09
Change ($) 0.13
Change (%) 2.55%
Day's Open 5.18
Day's Range 5.13 - 5.42
Day's Volume 1,109,270
52-Week Range 4.75 - 15.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 58.18% and 58.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...

2 weeks ago - Business Wire

Syros Pharmaceuticals, Inc. (SYRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further str...

1 month ago - Zacks Investment Research

Catherine Wood ( Trades , Portfolio )'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (NASDAQ:ONVO) position alongside a small reduction in the Syros Pharmaceuti...

Other stocks mentioned: ONVO
2 months ago - GuruFocus

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -12.96% and 78.06%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter an...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that members of its management team...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell shares ...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expecte...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7) The updated release reads: SYROS TO PRESENT AT 39TH ANNUAL J.P. MORGAN HE...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...

4 months ago - Business Wire

Syros Pharmaceuticals doubled its stock price in 2020. Syros recently acquired SY-2101 from Orsenix.

4 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has closed a previously ann...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new clinical data from its Phase 2 ...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, ...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...

5 months ago - Business Wire

Syros Pharmaceuticals' (SYRS) CEO Nancy Simonian on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new clinical d...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacokinetics (P...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data f...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of S.

8 months ago - Business Wire

Syros (SYRS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 5.00% and 45.57%, respectively, for the quarter ended June 2020.

9 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...

9 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, J...

9 months ago - Business Wire

Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...

9 months ago - Business Wire

Top Ranked Momentum Stocks to Buy for May 19th

Other stocks mentioned: AGFS, MIST, UNFI
11 months ago - Zacks Investment Research

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Syros Pharmaceuticals Inc (SYRS) delivered earnings and revenue surprises of 13.33% and 38.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) were unchanged in pre-market trading after the company reported Q1 results.

1 year ago - Benzinga

Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

Syros, Beyond Oncology

1 year ago - Seeking Alpha

Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 2.13% and -35.53%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

Syros Pharmaceuticals Update: Still A Buy

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor Syros Pharmaceuticals

1 year ago - Zacks Investment Research

Investors appeared to like the addition of a well-known new board member.

1 year ago - The Motley Fool

Syros Pharmaceuticals (SYRS) news for Wednesday about plans for developing new drugs and a $20 million payment have SYRS stock flying high.

1 year ago - InvestorPlace

Global Blood Therapeutics Inc. and Syros Pharmaceuticals announced a partnership to develop and commercialize therapies for sickle cell disease and beta thalassemia.

Other stocks mentioned: GBT
1 year ago - Market Watch

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.

Other stocks mentioned: ACAD, ALEC, AMRN, AVDL, BHC, BIIB, EPZM ...
1 year ago - 24/7 Wall Street

Syros Pharmaceuticals' (SYRS) CEO Nancy Simonian on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About SYRS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 30, 2016
CEO
Nancy Simonian
Employees
103
Stock Exchange
NASDAQ
Ticker Symbol
SYRS
Full Company Profile

Financial Performance

In 2020, SYRS's revenue was $15.09 million, an increase of 661.50% compared to the previous year's $1.98 million. Losses were -$84.04 million, 11.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for SYRS stock is "Buy." The 12-month stock price forecast is 16.57, which is an increase of 217.43% from the latest price.

Price Target
$16.57
(217.43% upside)
Analyst Consensus: Buy